Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.
about
The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agentsCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationA putative pH-dependent nuclear localization signal in the juxtamembrane region of c-MetMutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseProtein mislocalization: mechanisms, functions and clinical applications in cancer.Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells.Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancerNuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor familyNuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma.A genetic view of laryngeal cancer heterogeneityHER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking.Identification of the zinc finger 216 (ZNF216) in human carcinoma cells: a potential regulator of EGFR activity.Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.Reversion of the ErbB malignant phenotype and the DNA damage response.DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceOpportunities and challenges of radiotherapy for treating cancer.Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage.Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.Omega-3 fatty acid supplementation in cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells?Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment.Erlotinib-induced rash spares previously irradiated skin.EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.Possible mechanisms and function of nuclear trafficking of the colony-stimulating factor-1 receptor.[Experimental tumor therapy].[Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
P2860
Q24304487-50F46648-0939-4BB9-86A2-A31DB0D49672Q26771165-484CF4AE-5D2A-4BB1-94EE-0F1892FB6095Q30596960-BF4DE661-391F-4D40-8F0A-72D8B104EF91Q31162700-53901FB2-3715-46A8-86A5-4FB64A5B8B66Q34076405-63E379ED-359D-4950-B670-36B3DD04A2F6Q34077207-EB4B5769-40BB-4751-8D29-C3DF9A62549AQ34283213-F61C6B71-3A95-4F41-8AC3-66D072C2422DQ34294881-C5EEA887-883A-4F9B-8497-42003B8C379FQ35551805-B2D38615-2C13-4A13-96F7-E7F6F2B09E01Q36162605-09B0EF19-E724-4554-886E-4E2879490106Q36617162-6C420A79-11E6-42F8-B338-6AB376AA2C8CQ36972817-2C9F0E12-BCE6-40FA-8F16-94D9F3A079B4Q37269081-6817D5E9-59FA-4188-8EB1-F7201B1C850EQ37417599-39373DF4-3DF5-4AD2-A30E-393EF88F0F78Q37688876-53AF7329-774B-42F4-9EC2-A9E6D328125EQ37690877-BE3F1239-420B-4CF1-BD73-6AC039A82CE1Q38047648-803D8BEB-3D77-4332-A500-F89125C1740DQ38106985-79EFCA94-5910-4AD5-B218-2A51632C4BB3Q38118934-C13BD91E-FC94-48A5-B2DC-62797F4D98DBQ38539957-D8801BC9-FB74-43CF-BA88-E036BDFC0F62Q38751317-03009B63-B7BA-4E83-9ECD-6D9D89ABA326Q39300555-704A9B2A-4875-4546-8FD9-1B7845BBB255Q39602655-2865E4FF-F888-453E-9647-AD289759E482Q42085614-51294CF2-6F42-4603-B15E-EBCDDB30E973Q44294451-0674D237-2E7E-49F7-9DFB-106D62E7BDA0Q45875804-7742F9B8-08CA-498B-8B76-5DA7D1D51E02Q48269479-B30066CE-0E0B-449F-A635-864DEB31FF96Q53211347-79A47685-9EB6-4805-80E0-C4E11727258DQ53284577-1BB3BAE9-C990-436F-90CB-B5B9195B4BE8Q54341722-D70CD267-0AA4-4C53-8358-7BB227A91CE3Q54490610-A0D03CD7-087E-42BA-A82A-790AFC95E907Q54548371-7AB75560-BA31-4908-824D-C6ED0C9C81C9
P2860
Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@en
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@nl
type
label
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@en
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@nl
prefLabel
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@en
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@nl
P2093
P2860
P1476
Nuclear EGFR as novel therapeu ...... ar translocation and function.
@en
P2093
Claus Mayer
H Peter Rodemann
Klaus Dittmann
P2860
P2888
P356
10.1007/S00066-009-2026-4
P577
2009-12-28T00:00:00Z